

Volume 72, Number 7, February 17, 2009, Supplement 2 www.neurology.org

THE MOST WIDELY READ AND HIGHLY CITED PEER-REVIEWED NEUROLOGY JOURNAL



| INTRODUCTION |  | S39 | When and how should treatment be started in                   |
|--------------|--|-----|---|
| S1           | Premotor Parkinson disease Eduardo Tolosa and Werner Poewe |     | Parkinson disease? Anthony E. Lang                            |
|              | Laddrao roiosa ana werner roewe                            |     | Anthony E. Lang   |
| ARTICLES     |  |     |   |
| S2           | The Parkinson chimera                                      | S44 | Molecular and clinical pathways to neuroprotection of         |
|              | Andrew J. Lees   |     | dopaminergic drugs in Parkinson disease Anthony H.V. Schapira |
| S12          | Diagnosis and the premotor phase of Parkinson disease      |     |   |
|              | Eduardo Tolosa, Carles Gaig, Joan Santamaría,              | S51 | "Disease-modification" trials in Parkinson disease:           |
|              | and Yaroslau Compta  |     | Target populations, endpoints and study design Olivier Rascol |
| S21          | Can we image premotor Parkinson disease?                   |     |   |
|              | Kenneth Marek and Danna Jennings                           |     |   |
| 007          | Consideration of the control of the Police of              | S59 | Can we achieve neuroprotection with currently                 |
| S27          | Genomic and proteomic biomarkers for Parkinson disease     |     | available anti-parkinsonian interventions?  C. Warren Olanow  |
|              | Thomas Gasser  |     | C. Warren Olanow  |
|              | mornus dusser  |     |   |
| S32          | Mechanisms compensating for dopamine loss in early         | S65 | Treatments for Parkinson disease—past                         |
|              | Parkinson disease  |     | achievements and current clinical needs                       |
|              | Jonathan Brotchie and Cheryl Fitzer-Attas                  |     | Werner Poewe  |

The supplement is funded by an unrestricted educational grant from Teva Pharmaceutical Industries Ltd. (Israel), Teva Neuroscience, Inc. (USA) and H. Lundbeck A/S (Denmark).



## **72 (7 Supplement 2)** *Neurology* 2009;72;S59-S73

## This information is current as of February 17, 2009

**Updated Information &** including high resolution figures, can be found at:

Services http://n.neurology.org/content/72/7\_Supplement\_2.citation.full

**Permissions & Licensing** Information about reproducing this article in parts (figures, tables) or in

its entirety can be found online at:

http://www.neurology.org/about/about\_the\_journal#permissions

**Reprints** Information about ordering reprints can be found online:

http://n.neurology.org/subscribers/advertise

*Neurology* ® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright . All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.

